Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotavirus W179-9 vaccine - Merck & Co

Drug Profile

Rotavirus W179-9 vaccine - Merck & Co

Alternative Names: Pentavalent-rotavirus-vaccine-W179-9-Merck-and-Co; PRV-Merck-and-Co; RotaTeq; Rotavirus vaccine, live, oral, pentavalent; Rotavirus-vaccine-live-oral-pentavalent-W179-9-Merck-and-Co; Rotavirus-W179-9-vaccine-Merck-and-Co; RV5; V260

Latest Information Update: 16 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Banyu; Chongqing Zhifei Biological Products; Merck & Co
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections
  • Phase III Pneumococcal infections

Most Recent Events

  • 18 Oct 2018 Phase-III clinical trials in Pneumococcal infections (In infants, In neonates, In volunteers) in Puerto Rico, USA (PO) (NCT03620162)
  • 08 Aug 2018 Merck Sharp & Dohme plans the phase III PNEU-DIRECTION trial for Pneumococcal Infections (In infants, In neonates, In volunteers) in USA in October 2018 (PO) (NCT03620162)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top